logo
Frequent Nightmares Linked to Faster Aging and Premature Death

Frequent Nightmares Linked to Faster Aging and Premature Death

Gizmodo5 days ago

If you often have nightmares, you may need to worry a bit more about your health.
New research presented today at the European Academy of Neurology (EAN) Congress 2025 links frequent nightmares to faster biological aging and an over three times higher risk of premature death, even when taking into account other medical conditions. The researchers claim to be the first to demonstrate this association, which could have significant implications for how seriously one should consider persistent nightmares.
'Our sleeping brains cannot distinguish dreams from reality,' Abidemi Otaiku, a neuroscientist at Imperial College London and presumably an author of a forthcoming study, explained in an EAN press release. 'That's why nightmares often wake us up sweating, gasping for breath, and with our hearts pounding – because our fight-or-flight response has been triggered. This stress reaction can be even more intense than anything we experience while awake.'
Simply put, researchers tracked the nightmare frequency of adults and children (whose nightmares were reported by their parents) for time periods of up to 19 years. Their results demonstrate that both children and adults who often have nightmares experience accelerated biological aging. Adults who suffered from weekly nightmares were also more than three times as likely to die before the age of 70 as those who rarely or never had nightmares, with the faster biological aging accounting for around 40% of that increased early mortality risk.
'Nightmares lead to prolonged elevations of cortisol, a stress hormone closely linked to faster cellular ageing,' Otaiku added. 'For those who frequently experience nightmares, this cumulative stress may significantly impact the ageing process. Additionally, nightmares disrupt both sleep quality and duration, impairing the body's essential overnight cellular restoration and repair. The combined effects of chronic stress and disrupted sleep likely contribute to the accelerated ageing of our cells and bodies.'
Specifically, the link between chronic nightmares and faster aging was consistent in participants of all sexes, ages, mental health statuses, and ethnicities. Biological aging was measured by looking at people's telomeres, the protective end caps of chromosomes. Shorter telomeres are widely considered to be a sign of greater biological age.
Furthermore, the research revealed weekly nightmares to more strongly predict early death than other widely known causes, including obesity, smoking, a bad diet, and low physical activity. Even less frequent nightmares, however, had their toll. Participants who reported having them monthly also experienced faster aging and increased premature mortality compared to those who reported rare or no nightmares.
As if living through terrifying experiences at night wasn't bad enough, the associated health consequences highlighted in the new research carry important implications for how seriously we should take nightmares.
And if we're being honest, the state of plastic pollution and human-driven accelerated geological processes are probably not helping in that category, either.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors
Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors

Yahoo

time6 hours ago

  • Yahoo

Medtronic (MDT) Appoints Dr. Joon Sup Lee to Board of Directors

Medtronic plc (NYSE:MDT) is one of the 11 best European stocks to invest in. On June 23, the company announced the appointment of Dr. Joon Sup Lee as an independent director to its Board of Directors. The appointment went into effect on June 18, 2025. A healthcare specialist in the laboratory testing an Oncology-related product. Dr. Lee's appointment was a result of Medtronic increasing the size of its Board. The new director will serve on the Board's Science and Technology Committee and the Compensation and Talent Committee. Dr. Lee is currently the CEO of Emory Healthcare, Inc., overseeing Georgia's most comprehensive academic health system. Before joining Emory Healthcare, Dr. Lee was the executive director of the University of Pittsburgh Medical Center's (UPMC) Heart and Vascular Institute from 2018 to 2020. He was also a professor of medicine at the University of Pittsburgh School of Medicine. He held various leadership roles at UPMC, including Director of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory. Medtronic plc (NYSE:MDT) is an Irish-domiciled healthcare technology company. It develops and sells medical devices and therapies for chronic conditions across four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Its top products include heart devices, spinal implants, surgical tools, insulin pumps, and neuromodulation systems. Medtronic serves over 79 million patients annually in more than 150 countries. While we acknowledge the potential of MDT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment
GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment

Yahoo

time6 hours ago

  • Yahoo

GSK (GSK) Gains FDA Approval for Benlysta Autoinjector for Lupus Treatment

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA approval for a 200 mg/mL autoinjector of Benlysta (belimumab) for the treatment of active lupus nephritis (LN). The approval applies to children aged five years and above. A pharmacist looking at a prescription bottle of gastrointestinal drugs. Benlysta autoinjector is the first-of-its-kind treatment option for at-home administration. The drug is a B-lymphocyte stimulator (BLyS)-specific inhibiting monoclonal antibody. It works by binding to soluble BLyS, which inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. It does not bind B cells directly. The 200 mg/mL autoinjector was previously approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024. Benlysta was the first and only approved biologic for both SLE and lupus nephritis in over 50 years, including for the pediatric population. The autoinjector will be available for patients and their caregivers immediately. GSK plc (NYSE:GSK) is a UK-based global biopharmaceutical company. It researches, develops, and sells medicines and vaccines for infectious diseases, HIV, respiratory conditions, cancer, and immune-related disorders. Its key products include Shingrix (shingles vaccine), Nucala (asthma), and HIV treatments through its ViiV Healthcare joint venture. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

Yahoo

time6 hours ago

  • Yahoo

Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion

Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the shares of Regulus ceased trading on the NASDAQ exchange, and the company became a fully owned subsidiary of Novartis. lucarista/ The acquisition marks a crucial step in the company's effort to advance the clinical development of a potential first-in-class medicine for autosomal dominant polycystic kidney disease. Regulus Joins Novartis with Farabursen, an investigational next-generation oligonucleotide aiming to reduce the growth of cysts and kidney size. Novartis is a global healthcare company dedicated to discovering and developing innovative medicines that improve and extend people's lives. It also focuses on addressing significant medical challenges, including cancer and rare genetic disorders, by prioritizing research and development, as well as innovative access approaches. Novartis AG (NYSE:NVS) is a global pharmaceutical company that discovers, develops, manufactures, and markets medicines to improve and extend people's lives. It also focuses on using science-based innovation to address significant healthcare challenges. Novartis operates in over 100 countries, with the US accounting for about one-third of its revenue. While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store